^
    2d
    A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=394, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P3 trial
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib) • rocbrutinib (LP-168)
    3d
    Bendamustine combined with Zuberitamab (BZ) followed by Orelabrutinib combined with Zuberitamab (OZ) in the treatment of newly diagnosed marginal zone lymphoma:A Phase II prospective clinical study (ChiCTR2500115104)
    P=N/A, N=74, Not yet recruiting, The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)
    3d
    A prospective observational study of Orelabrutinib combined with anti-CD20 monoclonal antibody followed by Orelabrutinib maintenance as first-line treatment for MZ (ChiCTR2500113665)
    P=N/A, N=40, Not yet recruiting, The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    3d
    Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study (ChiCTR2500115204)
    P2, N=46, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    6d
    Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. (clinicaltrials.gov)
    P2, N=23, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    13d
    Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma (clinicaltrials.gov)
    P4, N=88, Recruiting, Beijing Tongren Hospital
    New P4 trial
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Inokai (orelabrutinib)
    17d
    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=990, Not yet recruiting, Zenas BioPharma (USA), LLC | N=330 --> 990
    Enrollment change
    |
    Inokai (orelabrutinib)
    1m
    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=330, Not yet recruiting, Zenas BioPharma (USA), LLC
    New P3 trial
    |
    Inokai (orelabrutinib)
    2ms
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease (clinicaltrials.gov)
    P2, N=25, Recruiting, Ruijin Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • lisaftoclax (APG-2575)
    2ms
    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=705, Recruiting, Zenas BioPharma (USA), LLC | Initiation date: Sep 2025 --> Dec 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    Inokai (orelabrutinib)
    2ms
    Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=34, Recruiting, Peking University Third Hospital
    New trial
    |
    Inokai (orelabrutinib) • pomalidomide • Anruixi (zuberitamab)
    2ms
    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (clinicaltrials.gov)
    P2, N=79, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Initiation date: Jun 2025 --> Dec 2025
    Trial initiation date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib)